Government Restricts Cold Medicine Combinations for Young Children

Why in the News ?

The Health Ministry has restricted the manufacture, sale and distribution of fixed-dose combinations (FDCs) containing Chlorpheniramine Maleate and Phenylephrine Hydrochloride for children below four years, citing potential safety risks and availability of safer alternatives.

Government Restrictions and Safety Measures

•     The government has imposed restrictions on all FDCs containing Chlorpheniramine Maleate and Phenylephrine Hydrochloride intended for children below four years of age.
•     Manufacturers have been directed to prominently display a mandatory warning on the label, package insert and promotional material.
•     The prescribed warning states that the FDC should not be used in children below four years.
•     The measure aims to prevent inappropriate use of these combinations among young children and strengthen paediatric drug safety.
•     The government stated that these combinations may pose health risks to children below four, while safer therapeutic alternatives are available.
•     The decision follows recommendations of an Expert Committee and the Drug Technical Advisory Board (DTAB).

FDC Regulation and Public Health Concerns

•     A fixed-dose combination contains two or more active pharmaceutical ingredients in a single dosage form.
•     Such combinations can improve convenience and adherence when their ingredients have a clear therapeutic rationale.
•     However, inappropriate FDCs can create concerns related to unnecessary medication, adverse effects, drug interactions and inappropriate dosing, particularly among children.
•     In June 2026, the Health Ministry prohibited the manufacture, sale and distribution of 16 FDC drugs for human use across India.
•     The latest restriction reflects the government’s broader effort to ensure that medicines marketed for children meet appropriate safety and therapeutic standards.
•     Children require particular caution because their drug metabolism, dosage requirements and susceptibility to adverse effects can differ significantly from adults.

 Key points : Drug Regulation in India

•     The Ministry of Health and Family Welfare is responsible for overall policy regarding medicines and public health.
•     The Central Drugs Standard Control Organisation (CDSCO) functions as India’s national regulatory authority for pharmaceuticals and medical devices.
•     The Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945 form the core legal framework governing drugs.
•     The Drugs Technical Advisory Board (DTAB) provides technical advice to governments on matters related to drug regulation.
•     FDCs require regulatory scrutiny to ensure that their combined ingredients are safe, effective and therapeutically justified.
•     Regulation of paediatric medicines is particularly important because inappropriate formulations can increase the risk of adverse drug reactions and dosing errors.
•     The broader objective is to balance access to medicines, therapeutic effectiveness and patient safety.